Das Oropharynxkarzinom stellt aufgrund seiner weltweiten Inzidenzzunahme und Assoziation mit dem humanen Papillomavirus-16, aber auch chronischem Tabak- und Alkoholkonsum eine genetisch heterogene Tumorgruppe mit hoher prognostischer Diversität dar. Die auf Basis retrospektiver Daten erstellte 8. Edition der TNM-Klassifikation und die wenigen prospektiven Daten zur Therapiedesintensivierung ermahnen aktuell eher zu einem konservativen Vorgehen.
Abstract
Background Oropharynx carcinoma (OPSCC) is a genetically heterogeneous tumor group with high prognostic diversity due to its worldwide increase in incidence and the association with the human papillomavirus HPV 16, but also chronic tobacco/alcohol consumption.
Objective The review attempts to present the current view on therapy and prevention of OPSCC with respect to association with HPV 16.
Material & Methods The overview is based on the current relevant literature as well as current studies.
Results & Discussion The OPSCC presents itself as a very complex, genetically heterogeneous group of head and neck tumors, which should therefore be considered in detail. The currently contradictory trial situation of retrospective studies versus prospective trials, the current TNM classification (8th edition) and the scarce prospective data arguing for non-inferiority of therapy de-intensification attempts currently admonish to encourage a more conservative treatment.
Schlüsselwörter
Oropharynxkarzinom - HPV-16 - Therapiedeintensivierung - Therapiedeeskalation - Transorale Roboter-Chirurgie - TORS
Keywords
Oropharynx Carcinoma - HPV16 - Therapeutic Intensification - Transoral Robotic Surgery - TORS
